OncoMatch/Clinical Trials/NCT07257640
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
Is NCT07257640 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IL-5 CAR-T cells for hematologic diseases.
Treatment: IL-5 CAR-T cells — This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: IL5RA overexpression (≥50% of leukemic blasts)
Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy (imatinib, corticosteroids, interferon-α, chemotherapy)
Lab requirements
Liver function
serum total bilirubin ≤1.5 × uln, alt and ast ≤3 × uln
Cardiac function
left ventricular ejection fraction (lvef) >50% as assessed by echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify